Xingqi Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 335 million yuan, an increase of 97.75%
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Xingqi Pharmaceutical released its semi-annual report for 2025, with operating revenue of 1.163 billion yuan, a year-on-year increase of 30.38%. The net profit attributable to shareholders of the listed company was 335 million yuan, a year-on-year increase of 97.75%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 331 million yuan, a year-on-year increase of 96.30%. The basic earnings per share were 1.36 yuan
According to the Zhitong Finance APP, Xingqi Pharmaceutical (300573.SZ) released its semi-annual report for 2025, reporting an operating income of 1.163 billion yuan, a year-on-year increase of 30.38%. The net profit attributable to shareholders of the listed company was 335 million yuan, a year-on-year increase of 97.75%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 331 million yuan, a year-on-year increase of 96.30%. The basic earnings per share were 1.36 yuan